Myovant Sciences Ltd. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Mar 31, 2022	FY2021 12 months to Mar 31, 2021	FY2020 12 months to Mar 31, 2020	FY2019 12 months to Mar 31, 2019	FY2018 12 months to Mar 31, 2018
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Share-based compensation
Depreciation and amortization
Changes in the fair value of the Takeda warrant liability
Foreign currency translation adjustment
Depreciation
Non-cash interest expense
Loss on extinguishment of debt
Foreign currency transaction gain
Amortization of operating lease right-of-use assets
Other

Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Deferred tax assets
Amount due from related party
Income tax receivable
Other assets
Accounts payable
Interest payable (related party)
Accrued expenses
Interest payable
Accrued expenses and other current liabilities
Deferred revenue
Amounts due to Pfizer
Cost share advance from Pfizer
Deferred rent
Operating lease liabilities
Deferred interest payable
Amounts due to related parties
Other liabilities
Net cash (used in) provided by operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Sales of marketable securities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount
Initial public offering costs paid
Capital contribution -other
Proceeds from issuance of common shares, net of issuance costs paid
Public Equity Offering
Total proceeds from issuance of common shares, net of issuance costs paid
Cash capital contribution from RSL
Proceeds from related party debt financing
Proceeds from stock option exercises
Settlement of former majority shareholder common shares subscribed
Payments on third party debt financings and redemption fees
Payment of annual debt administration fee to NovaQuest
Due to RSL and RSI for amounts paid on behalf of the Company
Proceeds from third-party debt financing, net of financing costs paid
Payment of tax withholding on net settlement of share awards
Payment of third-party debt financings and redemption and administration fees
Net cash provided by financing activities

Net change in cash
Cash—beginning of period
Cash—end of period
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental Disclosure of Non-Cash Financing and Investing Information:
Acquisition of in-process research and development
Warrants issued to Hercules
Reclassification of share-based compensation awards from additional paid-in capital to current liabilities
Change in fair value of share-based awards recorded to additional paid-in capital
Reclassification of share-based compensation liabilities to additional paid-in capital upon settlement or maturity of awards
Equipment purchases included in accounts payable

Supplemental Disclosure of Cash Flow Information:
Income taxes paid
Interest paid
Interest (related party) paid

Comments